It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M
Between one Boston-based biotech run by some veteran stalwarts and two upstarts in the Bay Area, an extended hot streak of biotech IPOs has blasted past last year’s annual total. And even as analysts caution of a likely slowdown, we have one more IPO filing to suggest that the industry may yet challenge the high peak hit in 2014.
San Francisco-based Tricida $TCDA may not be as well known as many of the bean town biotechs to go public this year, but it nevertheless brought in a whopping $222 million haul on an upsized offering of shares that came it at $19 each — above the range.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.